Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 3, 2010, Pages 290-295

  Turkeri, Levent ^a   Onol, Fikret Fatih ^a   Ozyurek, Mustafa ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Dendritic cells; Immunotherapy; Prostate cancer

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 4; LACTATE DEHYDROGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TELOMERASE; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN LNCAP; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CELL SEPARATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE;

EID: 77951621656     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.01.029     Document Type: Article

References (28)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Garnick M.B. Prostate cancer: Screening, diagnosis, and management. Ann Int Med 118 (1993) 804-818
3. Simons J.W., and Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urol Oncol 24 (2006) 419-424
4. Tannock I.F., de Wit R., Berry W.R., et al. Docataxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
5. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
6. Tarassoff C.P., Arlen P.M., and Gulley J.L. Therapeutic vaccines for prostate cancer. Oncologist 11 (2006) 451-462
7. Kiessling A., Füssel S., Wehner R., et al. Advances in specific immunotherapy for prostate cancer. Eur Urol 53 (2008) 694-708
8. Small E.J., Fratesi P., Reese D.M., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 23 (2000) 3894-3903
9. Lin A.M., Hershberg R.M., and Small E.J. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol 24 (2006) 434-441
10. Pandha H.S., John R.J., Hutchinson J., et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumor lysate-pulsed cells: A phase I/II study. BJU Int 94 (2004) 412-418
11. Abdul M., and Hoosein N. Changes in β-2 microglobulin expression in prostate cancer. Urol Oncol 5 (2000) 168-172
12. Valenti M.T., Bertold F., Carbonare L.D., et al. The effect of biphosphonates on gene expression: GAPDH as a house-keeping or a new target gene?. BMC Cancer 6 (2006) 49-55
13. Schuler G., Schuler-Thurner B., and Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15 (2003) 138-147
14. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4 (2004) 11-22
15. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha. J Exp Med 179 (1994) 1109-1118
16. Bennett S.R., Carbone F.R., Karamalis F., et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186 (1997) 65-70
17. Ragde H., Cavanagh W.A., and Tjoa B.A. Dendritic cell based vaccines: Progress in immunotherapy studies for prostate cancer. J Urol 172 (2004) 2532-2538
18. Chakraborty N.G., Stevens R.L., Mehrotra S., et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 52 (2003) 497-505
19. Horiguchi Y., Nukaya I., Okazawa K., et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 8 (2002) 3885-3892
20. Peshwa M.V., Shi J.D., Ruegg C., et al. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36 (1998) 129-138
21. Kiessling A., Schmitz M., Stevanovic S., et al. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 102 (2002) 390-397
22. Jaffee E.M., Lazenby A., Meuer J., et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol 18 (1995) 1-9
23. Berard F., Blanco P., Davoust J., et al. Cross-priming of naïve CD8 cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192 (2000) 1535-1544
24. Akashi T., Koizumi K., Nagakawa O., et al. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 16 (2006) 831-836
25. Oikawa T., Kawai K., Ishiwata I., et al. Induction of potent antitumor natural-killer cells from peripheral blood of patients with advanced prostate cancer. BJU Int 92 (2003) 1009-1015
26. Sanda M.G., Ayyagari S.R., and Jaffee E.M. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151 (1994) 622-628
27. Simons J.W., Carducci M.A., Mikhak B., et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 12 (2006) 3394-3401
28. Small E.J., Sacks N., Nemunaitis J., et al. Granulocyte macrophage colony-stimulating factor-secreting allogenic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13 (2007) 3883-3891